Skip to main content
Top
Published in: Journal of Thrombosis and Thrombolysis 2/2017

01-08-2017

Central aortic pulse pressure, thrombogenicity and cardiovascular risk

Authors: Gailing Chen, Kevin P. Bliden, Rahul Chaudhary, Fang Liu, Himabindu Kaza, Eliano P. Navarese, Udaya S. Tantry, Paul A. Gurbel

Published in: Journal of Thrombosis and Thrombolysis | Issue 2/2017

Login to get access

Abstract

High central aortic pulse pressure (CPP) and thrombin-induced platelet–fibrin clot strength (TIP–FCS) have been associated with ischemic outcomes in patients with coronary artery disease in separate studies. But, the ischemic risk associated with these factors has never been analyzed in a single study and their interrelation is unknown. The primary aim of the study was to establish cut points for CPP and TIP–FCS measured at the time of catheterization associated with long term major adverse cardiovascular events. We enrolled 334 consecutive patients undergoing cardiac catheterization and assessed thrombogenicity by thrombelastography. Patients were followed up to 3 years. The primary endpoint was a composite of cardiovascular death, myocardial infarction, and ischemic stroke and the secondary endpoint was occurrence of the primary endpoint or recurrent ischemic events requiring hospitalization. Patients with primary and secondary endpoint occurrence had higher CPP (83 ± 20 vs. 60 ± 18 mmHg, p < 0.0001; 70 ± 21 vs. 59 ± 18 mmHg, p < 0.0001, respectively) and TIP–FCS (68.5 ± 5.8 vs. 65.5 ± 5.0 mm, p = 0.008; 67.4 ± 5.9 vs. 65.2 ± 4.8 mm, p = 0.001, respectively). CPP >60 mmHg and TIP–FCS >69 mm were both independent predictors of primary endpoint occurrence (p = 0.0001 and p = 0.02, respectively). ROC analysis for CPP and TIP–FCS showed a C-statistic of 0.81 (p < 0.0001) and 0.68 (p = 0.007) for the primary endpoint, respectively. Patients with CPP >60 mmHg had higher TIP–FCS (66.8 ± 5.1 vs. 64.8 ± 5.0 mm, p < 0.001) and primary and secondary endpoint occurrence (13 vs. 1.1%, p < 0.0001 and 31.8 vs. 14.4%, p = 0.0002, respectively). CPP >60 mmHg + TIP–FCS > 69 mm was associated with a markedly increased risk of primary endpoint occurrence [HR (95% CI) 5.4(2.3–12.5), p = 0.0001]. High CPP and thrombogenicity are interrelated; each are independently associated with increased cardiovascular risk; and simultaneous presence markedly enhances risk. The mechanistic link between CPP and thrombogenicity deserves further study.
Literature
1.
go back to reference Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP, Bassi AK, Tantry US (2005) Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING study. J Am Coll Cardiol 46:1820–1826CrossRefPubMed Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP, Bassi AK, Tantry US (2005) Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING study. J Am Coll Cardiol 46:1820–1826CrossRefPubMed
2.
go back to reference Gkaliagkousi E, Corrigall V, Becker S, de Winter P, Shah A, Zamboulis C, Ritter J, Ferro A (2009) Decreased platelet nitric oxide contributes to increased circulating monocyte-platelet aggregates in hypertension. Eur Heart J 30:3048–3054CrossRefPubMed Gkaliagkousi E, Corrigall V, Becker S, de Winter P, Shah A, Zamboulis C, Ritter J, Ferro A (2009) Decreased platelet nitric oxide contributes to increased circulating monocyte-platelet aggregates in hypertension. Eur Heart J 30:3048–3054CrossRefPubMed
3.
go back to reference Erdogan D, Icli A, Aksoy F, Akcay S, Ozaydin M, Ersoy I, Varol E, Dogan A (2013) Relationships of different blood pressure categories to indices of inflammation and platelet activity in sustained hypertensive patients with uncontrolled office blood pressure. Chronobiol Int 30:973–980CrossRefPubMed Erdogan D, Icli A, Aksoy F, Akcay S, Ozaydin M, Ersoy I, Varol E, Dogan A (2013) Relationships of different blood pressure categories to indices of inflammation and platelet activity in sustained hypertensive patients with uncontrolled office blood pressure. Chronobiol Int 30:973–980CrossRefPubMed
4.
go back to reference Varol E, Akcay S, Icli A, Yucel H, Ozkan E, Erdogan D, Ozaydin M (2010) Mean platelet volume in patients with prehypertension and hypertension. Clin Hemorheol Microcirc 45:67–72PubMed Varol E, Akcay S, Icli A, Yucel H, Ozkan E, Erdogan D, Ozaydin M (2010) Mean platelet volume in patients with prehypertension and hypertension. Clin Hemorheol Microcirc 45:67–72PubMed
5.
go back to reference Gkaliagkousi E, Passacquale G, Douma S, Zamboulis C, Ferro A (2010) Platelet activation in essential hypertension: implications for antiplatelet treatment. Am J Hypertens 23:229–236CrossRefPubMed Gkaliagkousi E, Passacquale G, Douma S, Zamboulis C, Ferro A (2010) Platelet activation in essential hypertension: implications for antiplatelet treatment. Am J Hypertens 23:229–236CrossRefPubMed
6.
7.
go back to reference Gurbel PA, Bliden KP, Kreutz RP, Dichiara J, Antonino MJ, Tantry US (2009) The link between heightened thrombogenicity and inflammation: pre-procedure characterization of the patient at high risk for recurrent events after stenting. Platelets 20:97–104CrossRefPubMed Gurbel PA, Bliden KP, Kreutz RP, Dichiara J, Antonino MJ, Tantry US (2009) The link between heightened thrombogenicity and inflammation: pre-procedure characterization of the patient at high risk for recurrent events after stenting. Platelets 20:97–104CrossRefPubMed
8.
go back to reference Jeong YH, Bliden KP, Shuldiner AR, Tantry US, Gurbel PA (2014) Thrombin-induced platelet-fibrin clot strength: relation to high on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes. Thromb Haemost 111:713–724CrossRefPubMed Jeong YH, Bliden KP, Shuldiner AR, Tantry US, Gurbel PA (2014) Thrombin-induced platelet-fibrin clot strength: relation to high on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes. Thromb Haemost 111:713–724CrossRefPubMed
9.
go back to reference Huang CM, Wang KL, Cheng HM, Chuang SY, Sung SH, Yu WC, Ting CT, Lakatta EG, Yin FC, Chou P, Chen CH (2011) Central versus ambulatory blood pressure in the prediction of all-cause and cardiovascular mortalities. J Hypertens 29:454–459CrossRefPubMedPubMedCentral Huang CM, Wang KL, Cheng HM, Chuang SY, Sung SH, Yu WC, Ting CT, Lakatta EG, Yin FC, Chou P, Chen CH (2011) Central versus ambulatory blood pressure in the prediction of all-cause and cardiovascular mortalities. J Hypertens 29:454–459CrossRefPubMedPubMedCentral
10.
go back to reference Vlachopoulos C, Aznaouridis K, O’Rourke MF, Safar ME, Baou K, Stefanadis C (2010) Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. Eur Heart J 31:1865–1871CrossRefPubMed Vlachopoulos C, Aznaouridis K, O’Rourke MF, Safar ME, Baou K, Stefanadis C (2010) Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. Eur Heart J 31:1865–1871CrossRefPubMed
11.
go back to reference Franklin SS, Khan SA, Wong ND, Larson MG, Levy D (1999) Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham heart study. Circulation 100:354–360CrossRefPubMed Franklin SS, Khan SA, Wong ND, Larson MG, Levy D (1999) Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham heart study. Circulation 100:354–360CrossRefPubMed
12.
go back to reference Philippe F, Chemaly E, Blacher J, Mourad JJ, Dibie A, Larrazet F, Laborde F, Safar ME (2002) Aortic pulse pressure and extent of coronary artery disease in percutaneous transluminal coronary angioplasty candidates. Am J Hypertens 15:672–677CrossRefPubMed Philippe F, Chemaly E, Blacher J, Mourad JJ, Dibie A, Larrazet F, Laborde F, Safar ME (2002) Aortic pulse pressure and extent of coronary artery disease in percutaneous transluminal coronary angioplasty candidates. Am J Hypertens 15:672–677CrossRefPubMed
13.
go back to reference Lin MJ, Chen CY, Lin HD, Lin CS, Wu HP (2016) Prognostic significance of central pulse pressure for mortality in patients with coronary artery disease receiving repeated percutaneous coronary intervention. Medicine 95:e3218.CrossRefPubMedPubMedCentral Lin MJ, Chen CY, Lin HD, Lin CS, Wu HP (2016) Prognostic significance of central pulse pressure for mortality in patients with coronary artery disease receiving repeated percutaneous coronary intervention. Medicine 95:e3218.CrossRefPubMedPubMedCentral
14.
go back to reference Mahla E, Suarez TA, Bliden KP, Rehak P, Metzler H, Sequeira AJ, Cho P, Sell J, Fan J, Antonino MJ, Tantry US, Gurbel PA (2012) Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET-CABG) study. Circ Cardiovasc Interv 5:261–269CrossRefPubMed Mahla E, Suarez TA, Bliden KP, Rehak P, Metzler H, Sequeira AJ, Cho P, Sell J, Fan J, Antonino MJ, Tantry US, Gurbel PA (2012) Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET-CABG) study. Circ Cardiovasc Interv 5:261–269CrossRefPubMed
15.
go back to reference Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction (2012) Third universal definition of myocardial infarction. J Am Coll Cardiol 60:1581–1598CrossRefPubMed Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction (2012) Third universal definition of myocardial infarction. J Am Coll Cardiol 60:1581–1598CrossRefPubMed
16.
go back to reference Gurbel PA, Bliden KP, Navickas IA, Mahla E, Dichiara J, Suarez TA et al (2010) Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events. Am Heart J 160:346–354CrossRefPubMedPubMedCentral Gurbel PA, Bliden KP, Navickas IA, Mahla E, Dichiara J, Suarez TA et al (2010) Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events. Am Heart J 160:346–354CrossRefPubMedPubMedCentral
17.
go back to reference Tantry US, Bliden KP, Suarez TA, Kreutz RP, Dichiara J, Gurbel PA (2010) Hypercoagulability, platelet function, inflammation and coronary artery disease acuity: results of the Thrombotic Risk Progression (TRIP) study. Platelets 21:360–367CrossRefPubMed Tantry US, Bliden KP, Suarez TA, Kreutz RP, Dichiara J, Gurbel PA (2010) Hypercoagulability, platelet function, inflammation and coronary artery disease acuity: results of the Thrombotic Risk Progression (TRIP) study. Platelets 21:360–367CrossRefPubMed
18.
go back to reference Lev EI, Bliden KP, Jeong YH, Pandya S, Kang K, Franzese C et al (2014) Influence of race and sex on thrombogenicity in a large cohort of coronary artery disease patients. J Am Heart Assoc 3:e001167CrossRefPubMedPubMedCentral Lev EI, Bliden KP, Jeong YH, Pandya S, Kang K, Franzese C et al (2014) Influence of race and sex on thrombogenicity in a large cohort of coronary artery disease patients. J Am Heart Assoc 3:e001167CrossRefPubMedPubMedCentral
19.
go back to reference Ozkan G, Ulusoy S, Mentese A, Karahan SC, Cansiz M (2013) New marker of platelet activation, SCUBE1, is elevated in hypertensive patients. Am J Hypertens 26:748–753CrossRefPubMed Ozkan G, Ulusoy S, Mentese A, Karahan SC, Cansiz M (2013) New marker of platelet activation, SCUBE1, is elevated in hypertensive patients. Am J Hypertens 26:748–753CrossRefPubMed
20.
21.
go back to reference Coban E, Yazicioglu G, Berkant Avci A, Akcit F (2005) The mean platelet volume in patients with essential and white coat hypertension. Platelets 16:435–438CrossRefPubMed Coban E, Yazicioglu G, Berkant Avci A, Akcit F (2005) The mean platelet volume in patients with essential and white coat hypertension. Platelets 16:435–438CrossRefPubMed
22.
go back to reference Nadar SK, Blann AD, Kamath S, Beevers DG, Lip GY (2004) Platelet indexes in relation to target organ damage in high-risk hypertensive patients: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). J Am Coll Cardiol 44:415–422CrossRefPubMed Nadar SK, Blann AD, Kamath S, Beevers DG, Lip GY (2004) Platelet indexes in relation to target organ damage in high-risk hypertensive patients: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). J Am Coll Cardiol 44:415–422CrossRefPubMed
23.
go back to reference Inanc T, Kaya MG, Yarlioglues M, Ardic I, Ozdogru I, Dogan A et al (2010) The mean platelet volume in patients with non-dipper hypertension compared to dippers and normotensives. Blood Press 19:81–85CrossRefPubMed Inanc T, Kaya MG, Yarlioglues M, Ardic I, Ozdogru I, Dogan A et al (2010) The mean platelet volume in patients with non-dipper hypertension compared to dippers and normotensives. Blood Press 19:81–85CrossRefPubMed
24.
go back to reference Yarlioglues M, Kaya MG, Ardic I, Dogdu O, Kasapkara HA, Gunturk E et al (2011) Relationship between mean platelet volume levels and subclinical target organ damage in newly diagnosed hypertensive patients. Blood Press 20:92–97CrossRefPubMed Yarlioglues M, Kaya MG, Ardic I, Dogdu O, Kasapkara HA, Gunturk E et al (2011) Relationship between mean platelet volume levels and subclinical target organ damage in newly diagnosed hypertensive patients. Blood Press 20:92–97CrossRefPubMed
25.
go back to reference Lee AJ (1997) The role of rheological and haemostatic factors in hypertension. J Hum Hypertens 11:767–776CrossRefPubMed Lee AJ (1997) The role of rheological and haemostatic factors in hypertension. J Hum Hypertens 11:767–776CrossRefPubMed
26.
go back to reference Khaleghi M, Singletary LA, Kondragunta V, Bailey KR, Turner ST, Mosley TH Jr et al (2009) Haemostatic markers are associated with measures of vascular disease in adults with hypertension. J Hum Hypertens 23:530–537CrossRefPubMedPubMedCentral Khaleghi M, Singletary LA, Kondragunta V, Bailey KR, Turner ST, Mosley TH Jr et al (2009) Haemostatic markers are associated with measures of vascular disease in adults with hypertension. J Hum Hypertens 23:530–537CrossRefPubMedPubMedCentral
27.
go back to reference Yang P, Liu YF, Yang L, Wei Q, Zeng H (2010) Mechanism and clinical significance of the prothrombotic state in patients with essential hypertension. Clin Cardiol 33:E81–E86CrossRefPubMed Yang P, Liu YF, Yang L, Wei Q, Zeng H (2010) Mechanism and clinical significance of the prothrombotic state in patients with essential hypertension. Clin Cardiol 33:E81–E86CrossRefPubMed
28.
go back to reference Jankowski P, Kawecka-Jaszcz K, Czarnecka D, Brzozowska-Kiszka M, Styczkiewicz K, Styczkiewicz M et al (2004) Ascending aortic, but not brachial blood pressure-derived indices are related to coronary atherosclerosis. Atherosclerosis 176:151–155CrossRefPubMed Jankowski P, Kawecka-Jaszcz K, Czarnecka D, Brzozowska-Kiszka M, Styczkiewicz K, Styczkiewicz M et al (2004) Ascending aortic, but not brachial blood pressure-derived indices are related to coronary atherosclerosis. Atherosclerosis 176:151–155CrossRefPubMed
29.
go back to reference Nishijima T, Nakayama Y, Tsumura K, Yamashita N, Yoshimaru K, Ueda H et al (2001) Pulsatility of ascending aortic blood pressure waveform is associated with an increased risk of coronary heart disease. Am J Hypertens 14:469–473CrossRefPubMed Nishijima T, Nakayama Y, Tsumura K, Yamashita N, Yoshimaru K, Ueda H et al (2001) Pulsatility of ascending aortic blood pressure waveform is associated with an increased risk of coronary heart disease. Am J Hypertens 14:469–473CrossRefPubMed
30.
go back to reference Roman MJ, Devereux RB, Kizer JR, Okin PM, Lee ET, Wang W et al (2009) High central pulse pressure is independently associated with adverse cardiovascular outcome the strong heart study. J Am Coll Cardiol 54:1730–1734CrossRefPubMedPubMedCentral Roman MJ, Devereux RB, Kizer JR, Okin PM, Lee ET, Wang W et al (2009) High central pulse pressure is independently associated with adverse cardiovascular outcome the strong heart study. J Am Coll Cardiol 54:1730–1734CrossRefPubMedPubMedCentral
31.
go back to reference Roman MJ, Devereux RB, Kizer JR, Lee ET, Galloway JM, Ali T et al (2007) Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. Hypertension 50:197–203CrossRefPubMed Roman MJ, Devereux RB, Kizer JR, Lee ET, Galloway JM, Ali T et al (2007) Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. Hypertension 50:197–203CrossRefPubMed
32.
go back to reference Safar ME, Blacher J, Pannier B, Guerin AP, Marchais SJ, Guyonvarc’h PM et al (2002) Central pulse pressure and mortality in end-stage renal disease. Hypertension 39:735–738CrossRefPubMed Safar ME, Blacher J, Pannier B, Guerin AP, Marchais SJ, Guyonvarc’h PM et al (2002) Central pulse pressure and mortality in end-stage renal disease. Hypertension 39:735–738CrossRefPubMed
33.
go back to reference Diamond SL (2016) Flow and delta-P dictate where thrombin, fibrin, and von Willebrand factor will be found. Thromb Res 141(Suppl 2):S22–S24CrossRefPubMed Diamond SL (2016) Flow and delta-P dictate where thrombin, fibrin, and von Willebrand factor will be found. Thromb Res 141(Suppl 2):S22–S24CrossRefPubMed
34.
go back to reference Duhamel TA, Xu YJ, Arneja AS, Dhalla NS (2007) Targeting platelets for prevention and treatment of cardiovascular disease. Expert Opin Ther Targets 11:1523–1533CrossRefPubMed Duhamel TA, Xu YJ, Arneja AS, Dhalla NS (2007) Targeting platelets for prevention and treatment of cardiovascular disease. Expert Opin Ther Targets 11:1523–1533CrossRefPubMed
Metadata
Title
Central aortic pulse pressure, thrombogenicity and cardiovascular risk
Authors
Gailing Chen
Kevin P. Bliden
Rahul Chaudhary
Fang Liu
Himabindu Kaza
Eliano P. Navarese
Udaya S. Tantry
Paul A. Gurbel
Publication date
01-08-2017
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 2/2017
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-017-1524-y

Other articles of this Issue 2/2017

Journal of Thrombosis and Thrombolysis 2/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.